In vivo relationship between thalamic nicotinic acetylcholine receptor occupancy rates and antiallodynic effects in a rat model of neuropathic pain: Persistent agonist binding inhibits the expression of antiallodynic effects

Synapse

Volumn 65, Issue 1, 2011, Pages 77-83

  Ueda, Masashi ^a,b   Iida, Yasuhiko ^c   Yoneyama, Tomoki ^b   Kawai, Tomoki ^b   Ogawa, Mikako ^d   Magata, Yasuhiro ^d   Saji, Hideo ^b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 125I iodo A 85380 ( 125I 5IA); Desensitization; Thalamus

Indexed keywords

5 IODO 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 5 IODO 3 (2 AZETIDINYLMETHOXY)PYRIDINE IODINE 125; NICOTINIC AGENT; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG RECEPTOR BINDING; IN VIVO STUDY; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; SCIATIC NERVE; SINGLE DRUG DOSE; TACTILE STIMULATION; THALAMUS;

ANALYSIS OF VARIANCE; ANIMALS; AUTORADIOGRAPHY; AZETIDINES; HYPERALGESIA; MALE; NEURALGIA; NICOTINIC AGONISTS; PHYSICAL STIMULATION; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; THALAMUS;

EID: 78049413678     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20819     Document Type: Article

References (44)

1. Bannon AW, Decker MW, Kim DJ, Campbell JE, Arneric SP. 1998. ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain. Brain Res 801: 158-163.
2. Bitner RS, Nikkel AL, Curzon P, Arneric SP, Bannon AW, Decker MW. 1998. Role of the nucleus raphe magnus in antinociception produced by ABT-594: Immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. J Neurosci 18: 5426-5432.
3. Bitner RS, Nikkel AL, Curzon P, Donnelly-Roberts DL, Puttfarcken PS, Namovic M, Jacobs IC, Meyer MD, Decker MW. 2000. Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res 871: 66-74.
4. 123I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers. Synapse 63: 339-358.
5. Buisson B, Vallejo YF, Green WN, Bertrand D. 2000. The unusual nature of epibatidine responses at the alpha4beta2 nicotinic acetylcholine receptor. Neuropharmacology 39: 2561-2569.
6. Changeux JP. 2010. Allosteric receptors: From electric organ to cognition. Annu Rev Pharmacol Toxicol 50: 1-38.
7. Court JA, Martin-Ruiz C, Graham A, Perry E. 2000. Nicotinic receptors in human brain: Topography and pathology. J Chem Neuroanat 20: 281-298.
8. Decker MW, Rueter LE, Bitner RS. 2004. Nicotinic acetylcholine receptor agonists: A potential new class of analgesics. Curr Top Med Chem 4: 369-384.
9. Dwoskin LP, Smith AM, Wooters TE, Zhang Z, Crooks PA, Bardo MT. 2009. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol 78: 732-743.
10. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. 1992. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41: 31-37.
11. 123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging 30: 1620-1629.
12. Gao B, Hierl M, Clarkin K, Juan T, Nguyen H, Valk M, Deng H, Guo W, Lehto SG, Matson D, McDermott JS, Knop J, Gaida K, Cao L, Waldon D, Albrecht BK, Boezio AA, Copeland KW, Harmange JC, Springer SK, Malmberg AB, McDonough SI. 2010. Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain. Pain 149: 33-49.
13. Gilbert SD, Clark TM, Flores CM. 2001. Antihyperalgesic activity of epibatidine in the formalin model of facial pain. Pain 89: 159-165.
14. Giniatullin R, Nistri A, Yakel JL. 2005. Desensitization of nicotinic ACh receptors: Shaping cholinergic signaling. Trends Neurosci 28: 371-378.
15. Iwamoto ET, Marion L. 1993. Adrenergic, serotonergic and cholinergic components of nicotinic antinociception in rats. J Pharmacol Exp Ther 265: 777-789.
16. Jain KK. 2004. Modulators of nicotinic acetylcholine receptors as analgesics. Curr Opin Investig Drugs 5: 76-81.
17. Khan IM, Buerkle H, Taylor P, Yaksh TL. 1998. Nociceptive and antinociceptive responses to intrathecally administered nicotinic agonists. Neuropharmacology 37: 1515-1525.
18. Kiguchi N, Maeda T, Tsuruga M, Yamamoto A, Yamamoto C, Ozaki M, Kishioka S. 2008. Involvement of spinal Met-enkephalin in nicotine-induced antinociception in mice. Brain Res 1189: 70-77.
19. Kudo T, Ueda M, Kuge Y, Mukai T, Tanaka S, Masutani M, Kiyono Y, Kizaka-Kondoh S, Hiraoka M, Saji H. 2009. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells. J Nucl Med 50: 942-949.
20. Lindstrom J, Anand R, Peng X, Gerzanich V, Wang F, Li Y. 1995. Neuronal nicotinic receptor subtypes. Ann N Y Acad Sci 757: 100-116.
21. Liu X, Vilenski O, Kwan J, Apparsundaram S, Weikert R. 2009. Unbound brain concentration determines receptor occupancy: A correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos 37: 1548-1556.
22. 123I-5IA SPECT. J Nucl Med 45: 1458-1470.
23. Mamede M, Ishizu K, Ueda M, Mukai T, Iida Y, Kawashima H, Fukuyama H, Togashi K, Saji H. 2007. Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. J Nucl Med 48: 1829-1835.
24. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove d'Exaerde A, Huchet M, Damaj MI, Changeux JP. 1999. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398: 805-810.
25. 3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists. Br J Pharmacol 157: 139-149.
26. 123I]5-IA-85380 SPECT. Neurobiol Aging 30: 1490-1497.
27. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment. J Nucl Med 50: 1455-1463.
28. Mukhin AG, Gundisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS, Chambers J, Vaupel DB, King SL, Picciotto MR, Innis RB, London ED. 2000. 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 57: 642-669.
29. 18F-FA-85380. J Nucl Med 49: 1628-1635.
30. Ogawa M, Tsukada H, Hatano K, Ouchi Y, Saji H, Magata Y. 2009. Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT). Biol Pharm Bull 32: 337-340.
31. 123I-5IA SPECT. J Neurol Sci 256: 52-60.
32. Paterson D, Nordberg A. 2000. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61: 75-111.
33. Paxinos G, Watson C. 2005. The rat brain in stereotaxic coordinates, 5th ed. San Diego: Elsevier Academic Press.
34. Perry DC, Xiao Y, Nguyen HN, Musachio JL, Davila-Garcia MI, Kellar KJ. 2002. Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. J Neurochem 82: 468-481.
35. Rowbotham MC, Duan WR, Thomas J, Nothaft W, Backonja MM. 2009. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain 146: 245-252.
36. Rueter LE, Kohlhaas KL, Curzon P, Surowy CS, Meyer MD. 2003. Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain. Pain 103: 269-276.
37. Saji H, Ogawa M, Ueda M, Iida Y, Magata Y, Tominaga A, Kawashima H, Kitamura Y, Nakagawa M, Kiyono Y, Mukai T. 2002. Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Ann Nucl Med 16: 189-200.
38. Seltzer Z, Dubner R, Shir Y. 1990. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43: 205-218.
39. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: Feasibility and reproducibility. J Nucl Med 46: 1466-1472.
40. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. 2009. Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 8: 733-750.
41. 123I]Iodo-A-85380: Assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. Ann Nucl Med 18: 337-344.
42. Ueda M, Iida Y, Kitamura Y, Kawashima H, Ogawa M, Magata Y, Saji H. 2008. 5-Iodo-A-85380, a specific ligand for alpha4beta2 nicotinic acetylcholine receptors, prevents glutamate neurotoxicity in rat cortical cultured neurons. Brain Res 1199: 46-52.
43. Ueda M, Iida Y, Tominaga A, Yoneyama T, Ogawa M, Magata Y, Nishimura H, Kuge Y, Saji H. 2010. Nicotinic acetylcholine receptors expressed in the ventral posterolateral thalamic nucleus play an important role in anti-allodynic effects. Br J Pharmacol 159: 1201-1210.
44. Young T, Wittenauer S, Parker R, Vincler M. 2008. Peripheral nerve injury alters spinal nicotinic acetylcholine receptor pharmacology. Eur J Pharmacol 590: 163-169.